$SRPT News
Last published 2d ago
- 2d agoSRPTGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - SAREPTA THERAPEUTICS INCEarnings Call TranscriptsGood afternoon, and thank you for joining Guggenheim's third Healthcare Innovation Conference. I am Dabjit, one of the therapeutic analysts, and my privilege to host Michael Severino, the CEO of Serapta Therapeutics. Tha
- 2d agoSRPTGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - SAREPTA THERAPEUTICS INCEarnings Call TranscriptsGood afternoon, and thank you for joining Guggenheim's third Healthcare Innovation Conference. I am Dabjit, one of the therapeutic analysts, and my privilege to host Michael Severino, the CEO of Serapta Therapeutics. Tha
- 6d agoSRPTSarepta Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoSRPTSarepta Therapeutics to Present at Upcoming Investor ConferencesBusiness WireSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following upcoming investor conferences on Nov. 9,
- 2w agoSRPTSarepta Therapeutics to Announce Third Quarter 2026 Financial ResultsBusiness WireSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2026 financial results after the Nasdaq Global Market closes on Thursday, Nov. 5, 2026.
- 4w agoSRPTSarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual MeetingBusiness WireCorrection of MBNL- dependent mis-splicing provides functional evidence that SRP-1003 is degrading disease-causing RNA within the nucleus. In a preclinical model, SRP-1003 reduced pathogenic DMPK mRNA in both the
- 1mo agoSRPTSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Sept. 30, 2026 that were previously approved by the Compensation Committee of its Board of
- 1mo agoSRPTSarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with DuchenneBusiness WirePatients treated with delandistrogene moxeparvovec at ages 8-12 demonstrated durable and clinically meaningful benefits across the North Star Ambulatory Assessment and timed function measures over 2 years compared to
- 1mo agoSRPTSarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual CongressBusiness WireSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data from its portfolio of treatments for Duchenne muscular dystrophy at the 31st Annual Congress
- 1mo agoSRPTSarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific MeetingBusiness WireSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data at the 27th Annual Neuromuscular Study Group (NMSG) Scientific Meeting, taking place Sept.
- 1mo agoSRPTSARTHESarepta Therapeutics - Morgan Stanley 24th Annual Global Healthcare Conference - SAREPTA THERAPEUTICS INCEarnings Call TranscriptsAll right, good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Michael. I'm one of the biotech analysts here, and it's my pleasure to introduce the team from Sarepta
- 1mo agoSRPTSARTHEMorgan Stanley 24th Annual Global Healthcare Conference - SAREPTA THERAPEUTICS INCEarnings Call TranscriptsAll right, good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Michael. I'm one of the biotech analysts here, and it's my pleasure to introduce the team from Sarepta
- 2mo agoSRPTSarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic YearBusiness WireRecipients include 20 individuals living with Duchenne and five siblings of individuals living with the condition Now in its ninth year, program has awarded more than 150 scholarships Sarepta Therapeutics, Inc.
- 2mo agoSRPTSarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare ConferenceBusiness WireSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 24th Annual Global
- 3mo agoSRPTSarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate DevelopmentsBusiness WireNew CEO Michael Severino, MD, brings extensive biopharma leadership and a proven track record of advancing innovation, building franchises, and delivering growth Net product revenues for the second quarter 2026
- 3mo agoSRPTSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 28, 2026, that were previously approved by its Board of Directors under Sarepta’s 2024
- 3mo agoSRPTSarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive OfficerBusiness Wire– Severino joins Sarepta’s Board of Directors – Doug Ingram to retire from Sarepta Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the
- 3mo agoSRPTSarepta Therapeutics to Announce Second Quarter 2026 Financial ResultsBusiness WireSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, Aug. 5, 2026.
- 4mo agoSRPTSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2026 that were previously approved by the Compensation Committee of its Board of
- 4mo agoSRPTSarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®Business Wire– Accepted for review with target action date of February 28, 2027 Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug
- 5mo agoSRPTGoldman Sachs 47th Annual Global Healthcare Conference - Sarepta TherapeuticsEarnings Call TranscriptsGreat. Good morning, everyone. It's my pleasure to introduce the Sarepta team. With us, we have Doug Ingram, CEO, Ian Estepan, President and COO, Ryan Wong, CFO, and Luis Rodino-Claypack, President of R&D. Thank you for
- 5mo agoCYDYMRNAOTLCRVMD+1Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 BillionGlobeNewswireAUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are
- 5mo agoSRPTSarepta Therapeutics to Participate in Upcoming Investor ConferencesBusiness WireSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following investor conferences in June: Goldman
- 6mo agoSRPTSarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceBusiness WireSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the RBC Capital Markets Global
- 6mo agoSRPTSarepta Therapeutics First Quarter 2026 Earnings Call - Sarepta TherapeuticsEarnings Call TranscriptsGood afternoon, and welcome to Sarepta's first quarter 2026 earnings results call. As a reminder, today's program is being recorded. I would now like to turn the call over to Tam Thornton, Sarefta's Director of Investor
- 6mo agoSRPTSarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate DevelopmentsBusiness WireNet product revenues for the first quarter 2026 totaled $330.5 million, consisting of $102.0 million of ELEVIDYS net product revenue and $228.6 million of PMO net product revenues Achieved GAAP and non-GAAP
- 6mo agoSRPTSarepta Therapeutics to Announce First Quarter 2026 Financial ResultsBusiness WireSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, May 6, 2026.
- 6mo agoALNYARCTDNLIOTLC+1When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in BiotechGlobeNewswireAUSTIN, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value in a sector
- 7mo agoSRPTSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2026 that were previously approved by the Compensation Committee of its Board of
- 7mo agoSRPTPhase 1/2 Preliminary Data Readout for DM1 and FSHD Programs - SareptaEarnings Call TranscriptsGood morning, and welcome to SARAPTA's Preliminary Data Readout of its Phase 1-2 Studies for DM1 and FSHD. As a reminder, today's program is being recorded. At this time, I'll turn the call over to Doug Ingram, SARAPTAS
- 7mo agoSRPTSarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1Business WireIn early clinical results, Sarepta's αvβ6 integrin-targeted siRNA approach achieves high muscle concentrations without dose limiting toxicity for FSHD1 and DM1 Company to host investor call on March 25, 2026, at
- 7mo agoSRPTSarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1Business WireSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wed., March 25, 2026, at 8:30 am Eastern Time, the Company will host a webcast and conference
- 7mo agoSRPTSarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®Business Wire– Following feedback from FDA, Company intends to submit supplemental new drug applications to FDA by the end of April 2026 requesting conversion to traditional approval Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the
- 8mo agoSRPTSarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with DuchenneBusiness Wire- Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study - The enhanced immunosuppressive regimen is designed to mitigate the risk of acute liver
- 8mo agoSRPTTD Cowen 46th Annual Health Care Conference - Sarepta TherapeuticsEarnings Call TranscriptsAwesome. Thanks, everyone, for joining us at the Sarepta Fireside Chat at the 46th Annual TD Cowan Healthcare Conference. I'm covering analyst Ritu Baral, and with us from Sarefta today is Ian Estepan, President and COO.
- 8mo agoSRPTSarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship ProgramBusiness Wire– Applications for the 2026-2027 academic year will be accepted until May 15, 2026 – Scholarships will be awarded to up to 20 individuals living with Duchenne muscular dystrophy and up to five siblings of individuals
- 8mo agoSRPTSarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific CongressBusiness WireSeveral abstracts, including a late-breaking podium presentation and posters, bring forward accumulating long-term efficacy, safety and caregiver-reported insights that deepen understanding of dystrophin restoration
- 8mo agoSRPTSarepta Therapeutics Fourth Quarter 2025 Earnings Call - Sarepta TherapeuticsEarnings Call TranscriptsGood afternoon, and welcome to Sarepta's fourth quarter 2025 earnings results call. As a reminder, today's program is being recorded. At this time, I'll turn the call over to Tam Thornton, Sarefta's Director of Investor
- 8mo agoSRPTSarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate DevelopmentsBusiness WireNet product revenues for the full year 2025 totaled $1,864.3 million, consisting of $965.6 million of PMO net product revenue and $898.7 million of ELEVIDYS net product revenue Net product revenues for the fourth
- 8mo agoSRPTSarepta Therapeutics Announces Commercial Launch of ELEVIDYS in JapanBusiness Wire- Japan now offers ELEVIDYS gene therapy to children with Duchenne muscular dystrophy aged 3 years to less than 8 years - Company is eligible to receive a $40 million milestone payment upon first commercial sale in
- 8mo agoSRPTSarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care ConferenceBusiness WireSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the TD Cowen 46th Annual Health Care
- 9mo agoSRPTSarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial ResultsBusiness WireSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2025 financial results after the Nasdaq Global Market closes on Wednesday,
- 9mo agoSRPTSarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's DiseaseBusiness Wire– The first-in-human clinical study of SRP-1005, known as INSIGHTT, is expected to begin in the second quarter of 2026 Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare
- 9mo agoSRPTSarepta EMBARK Study 3 Year Topline Results - SareptaEarnings Call TranscriptsGood morning, and welcome to Sarepta's Embark three-year data top-line results call. As a reminder, today's program is being recorded. At this time, I'll turn the call over to Doug Ingram, Sarefta's Chief Executive Offic
- 9mo agoSRPTSarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne PatientsBusiness WireAt a mean age of 9 years old, ELEVIDYS-treated patients achieved mean North Star Ambulatory Assessment (NSAA) scores above baseline three years after treatment (n=52) ELEVIDYS gene therapy demonstrated 70% or
- 10mo agoSRPT2026 JP Morgan Healthcare Conference - JP MorganEarnings Call TranscriptsWelcome everyone to the 44th annual J.P. Morgan Healthcare Conference. My name is Anupam Rama, I'm one of the Senior Biotech Analysts here at J. P. Morgan. I'm joined by my squad, Joyce Zhou, Priyanka Grover, Rati Pinhe.
- 10mo agoSRPTApproval of Amondys 45, Nda #213026 (Labeling)FDA Approved DrugsApproval Date: 01/06/2026; Drug Name: Amondys 45, Nda #213026; Active Ingredients: CASIMERSEN; Company: Sarepta Theraps Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 213026
- 10mo agoSRPTSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Dec. 31, 2025 that were previously approved by the Compensation Committee of its Board of
- 11mo agoSRPTSarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027Business WireSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has entered into separate, privately negotiated exchange agreements with a limited number of
- 11mo agoSRPTSarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with DuchenneBusiness WireApproximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study, which is expected to begin before the end of the year The enhanced immunosuppressive